Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Publication|Articles|October 1, 2008
- ONCOLOGY Nurse Edition Vol 22 No 11
- Volume 22
- Issue 11
ONCOLOGY Nurse Edition October 2008, Vol 22 No 11
Advertisement
October 2008, Vol 22 No 11
Main Articles
Psychological Challenges After Cancer: A Guide for Clinical Practice Reviewed in:
The Recklitis et al Article Reviewed
LATE EFFECTS CLINIC: Post-Trauma Symptoms in Cancer Survivors
Graft-Versus-Host Disease: A Complex Long-Term Side Effect of Hematopoietic Stem Cell Transplant Reviewed in:
The Barton-Burke et al Article Reviewed
DRUG ESSENTIALS: Small Molecule Multitargeted TKI Therapy
PATIENT INFORMATION: Fatigue in People with Cancer
Articles in this issue
about 18 years ago
The Recklitis et al Article Reviewedabout 18 years ago
A Challenge of Survivorship-Healing the Mind and Spiritabout 18 years ago
Post-Trauma Symptoms in Cancer Survivorsabout 18 years ago
Small Molecule Multitargeted TKI Therapyabout 18 years ago
La fatiga en personas con cáncerabout 18 years ago
Fatigue in People With CancerAdvertisement
Related to this article
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across various treatment settings.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue following the withdrawal.
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5